GREAT NECK, N.Y.--(BUSINESS WIRE)--Neogenix Oncology, Inc. (Neogenix) announced today that it will present data from its new carcinoma biomarker (16C3). The company continues to use its platform to develop a portfolio of cancer markers for detection of cancer in blood and tumor samples. Neogenix has demonstrated the presence of the 16C3 antigen in a broad range of adenocarcinomas and presents its first results with this biomarker from patient serum samples.
